Back to Authors

Garfall, Alfred L.

https://orcid.org/0000-0003-2791-5748

A5035811221 | I79576946

Mayo Clinic

University of Pennsylvania

Citations 14

MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ā‰„4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal A

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7292-7293

10.1182/blood-2022-163260

NCCN GuidelinesĀ® Insights: Multiple Myeloma, Version 3.2022

Journal of the National Comprehensive Cancer Network | January 28, 2022 | Volume: 20 | Issue: 1 | Pages: 8-19

10.6004/jnccn.2022.0002 | PMID 34991075

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates/changes specific to the treatment of patients with multiple myeloma in the 2022 version of the guidelines.
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network | December 7, 2020 | Volume: 18 | Issue: 12 | Pages: 1685-1717

10.6004/jnccn.2020.0057 | PMID 33285522

Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, and newly diagnosed multiple myeloma.
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020

Journal of the National Comprehensive Cancer Network | October 7, 2019 | Volume: 17 | Issue: 10 | Pages: 1154-1165

10.6004/jnccn.2019.0049 | PMID 31590151

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma.